Tumor reversion holds promise
Tumor reversion holds promise |
https://doi.org/10.18632/oncotarget.131
Adam Telerman,
Robert Amson,
and Mary J.C. Hendrix
|
233-234 |
Addiction to B-MYB |
https://doi.org/10.18632/oncotarget.132
W. Clay Gustafson,
and William A. Weiss
|
235-236 |
The evolving picture of the glioblastoma genome
The evolving picture of the glioblastoma genome |
https://doi.org/10.18632/oncotarget.133
Donald W. Parsons
|
237-238 |
The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens
The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens |
https://doi.org/10.18632/oncotarget.134
Per thor Straten,
and Mads Hald Andersen
|
239-245 |
Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes
Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes |
https://doi.org/10.18632/oncotarget.135
Macus Tien Kuo,
Niramol Savaraj,
and Lynn G. Feun
|
246-251 |
A novel screen using the Reck tumor suppressor gene promoter detects both conventional and metastasis-suppressing anticancer drugs
A novel screen using the Reck tumor suppressor gene promoter detects both conventional and metastasis-suppressing anticancer drugs |
https://doi.org/10.18632/oncotarget.136
Ryuya Murai,
Yoko Yoshida,
Teruyuki Muraguchi,
Emi Nishimoto,
Yoko Morioka,
Hitoshi Kitayama,
Shinae Kondoh,
Yoshinori Kawazoe,
Masahiro Hiraoka,
Motonari Uesugi,
and Makoto Noda
|
252-264 |
Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes
Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes |
https://doi.org/10.18632/oncotarget.137
Christopher G. Duncan,
Patrick J. Killela,
Cathy A. Payne,
Benjamin Lampson,
William C. Chen,
Jeff Liu,
David Solomon,
Todd Waldman,
Aaron J. Towers,
Simon G. Gregory,
Kerrie L. McDonald,
Roger E. McLendon,
Darell D. Bigner,
and Hai Yan
|
265-277 |
Addiction of MYCN amplified tumours to B-MYB underscores a reciprocal regulatory loop
Addiction of MYCN amplified tumours to B-MYB underscores a reciprocal regulatory loop |
https://doi.org/10.18632/oncotarget.138
Francesco Gualdrini,
Daisy Corvetta,
Sandra Cantilena,
Olesya Chayka,
Barbara Tanno,
Giuseppe Raschellà,
and Arturo Sala
|
278-288 |
p300- and Myc-mediated regulation of glioblastoma multiforme cell differentiation
p300- and Myc-mediated regulation of glioblastoma multiforme cell differentiation |
https://doi.org/10.18632/oncotarget.139
Sreejith P. Panicker,
Baisakhi Raychaudhuri,
Pankaj Sharma,
Russell Tipps,
Tapati Mazumdar,
Asoke K. Mal,
Juan M. Palomo,
Michael A. Vogelbaum,
and S. Jaharul Haque
|
289-303 |
The secretory small GTPase Rab27B as a marker for breast cancer progression
The secretory small GTPase Rab27B as a marker for breast cancer progression |
https://doi.org/10.18632/oncotarget.140
An Hendrix,
Geert Braems,
Marc Bracke,
Miguel C. Seabra,
William A. Gahl,
Olivier De Wever,
and Wendy Westbroek
|
304-308 |
VEGF-independent angiogenic pathways induced by PDGF-C
VEGF-independent angiogenic pathways induced by PDGF-C |
https://doi.org/10.18632/oncotarget.141
Xuri Li,
Anil Kumar,
Fan Zhang,
Chunsik Lee,
Yang Li,
Zhongshu Tang,
and Pachiappan Arjunan
|
309-314 |